[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFyzWMq1kh3xdjf_cEKe5xizDHelfXE9XNUTWHV0LGj4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"Kyowa Kirin, Inc.",[4],36,false,2,9,5123,1,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"Parkinson's Disease",8,{"name":17,"count":18},"X-Linked Hypophosphatemia",3,{"name":20,"count":18},"X-linked Hypophosphatemia",{"name":22,"count":8},"Solid Tumor",{"name":24,"count":8},"Cancer",{"name":26,"count":8},"Carcinoma",{"name":28,"count":11},"Urothelial Carcinoma",{"name":30,"count":11},"Stage IV Melanoma",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT07192471","A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma","2029-03","KK2223",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,69,162,242,283,301,319,337,398,444,467,491,509,527,545,570,597,631,655,673,698,716,734,760,786,804,832],{"intervention":36,"totalTrials":11,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":61,"PHASE3":63,"PHASE4":65,"NA":67},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":11,"soonestReadout":35},[52],{"nctId":33,"briefTitle":34,"status":53,"phases":54,"primaryCompletion":35,"completion":55,"start":56,"enrollment":57,"conditions":58,"interventions":60},"NOT_YET_RECRUITING",[39],"2030-09","2026-07",72,[59],"T-cell NHL (PTCL or CTCL)",[36],{"trials":62,"activeCount":49},[],{"trials":64,"activeCount":49},[],{"trials":66,"activeCount":49},[],{"trials":68,"activeCount":49},[],{"intervention":70,"totalTrials":15,"cells":71},"Istradefylline",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":109,"PHASE4":158,"NA":160},{"trials":73,"activeCount":49},[],{"trials":75,"activeCount":49},[],{"trials":77,"activeCount":49},[78,91,100],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":90},"NCT00199446","Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome","COMPLETED",[40],"2006-08","2006-10","2005-07",160,[88,89],"Sleep Disorder","Restless Legs Syndrome",[70],{"nctId":92,"briefTitle":93,"status":81,"phases":94,"primaryCompletion":95,"completion":83,"start":96,"enrollment":86,"conditions":97,"interventions":99},"NCT00199433","A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients",[40],"2006-07","2005-05",[14,98],"Movement Disorder Syndrome",[70],{"nctId":101,"briefTitle":102,"status":81,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT00456794","12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg\u002FDay Istradefylline in Parkinson's Disease Patients on Levodopa\u002FCarbodopa",[40],"2003-10","2002-03",325,[14],[70],{"trials":110,"activeCount":49},[111,121,129,139,148],{"nctId":112,"briefTitle":113,"status":81,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT00199368","An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018",[41],"2007-03","2007-05","2004-10",1100,[14],[70],{"nctId":122,"briefTitle":123,"status":81,"phases":124,"primaryCompletion":104,"completion":104,"start":125,"conditions":126,"interventions":127},"NCT00955045","A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa\u002FCarbidopa Therapy",[40,41],"2002-08",[14],[128],"istradefylline",{"nctId":130,"briefTitle":131,"status":81,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT00199420","A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa",[41],"2005-11","2005-12","2004-07",580,[14],[70],{"nctId":140,"briefTitle":141,"status":81,"phases":142,"primaryCompletion":133,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT00199407","A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa",[41],"2006-01","2004-06",230,[14],[70],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT00199381","An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001","TERMINATED",[41],"2008-10","2005-10",504,[14],[70],{"trials":159,"activeCount":49},[],{"trials":161,"activeCount":49},[],{"intervention":163,"totalTrials":164,"cells":165},"burosumab",6,{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":204,"PHASE4":238,"NA":240},{"trials":167,"activeCount":49},[],{"trials":169,"activeCount":49},[],{"trials":171,"activeCount":49},[172,181,194],{"nctId":173,"briefTitle":174,"status":81,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT02163577","Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)",[40],"2018-10-30","2014-07-02",52,[20],[163],{"nctId":182,"briefTitle":183,"status":81,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":192},"NCT02304367","Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)",[40],"2017-07-27","2021-01-21","2015-03-24",17,[190,191],"Tumor Induced Osteomalacia (TIO)","Epidermal Nevus Syndrome (ENS)",[193],"Burosumab",{"nctId":195,"briefTitle":196,"status":81,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":203},"NCT02750618","Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)",[40],"2017-04-20","2019-09-10","2016-05-05",13,[17],[193],{"trials":205,"activeCount":49},[206,218,228],{"nctId":207,"briefTitle":208,"status":81,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT02915705","Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH",[41],"2018-02-12","2019-07-15","2016-09-08",61,[17],[163,216,217],"Oral Phosphate Supplement","active vitamin D",{"nctId":219,"briefTitle":220,"status":81,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT02526160","Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)",[41],"2016-12-22","2018-12-06","2015-10-22",134,[20],[163],{"nctId":229,"briefTitle":230,"status":81,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":237},"NCT02537431","Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)",[41],"2017-08-30","2018-12-13","2015-12-23",14,[20],[163],{"trials":239,"activeCount":49},[],{"trials":241,"activeCount":49},[],{"intervention":243,"totalTrials":8,"cells":244},"KW-0761",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":265,"PHASE4":279,"NA":281},{"trials":246,"activeCount":49},[],{"trials":248,"activeCount":49},[],{"trials":250,"activeCount":49},[251],{"nctId":252,"briefTitle":253,"status":81,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT01626664","KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)",[40],"2015-08","2018-02","2012-06",71,[260],"Adult T-cell Leukemia-Lymphoma",[243,262,263,264],"Pralatrexate","gemcitabine plus oxaliplatin","DHAP",{"trials":266,"activeCount":49},[267],{"nctId":268,"briefTitle":269,"status":81,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT01728805","Study of KW-0761 Versus Vorinostat in Relapsed\u002FRefractory CTCL",[41],"2017-03","2021-02-17","2012-11",372,[276],"Cutaneous T-Cell Lymphoma",[243,278],"Vorinostat",{"trials":280,"activeCount":49},[],{"trials":282,"activeCount":49},[],{"intervention":216,"totalTrials":11,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":297,"NA":299},{"trials":286,"activeCount":49},[],{"trials":288,"activeCount":49},[],{"trials":290,"activeCount":49},[],{"trials":292,"activeCount":49},[293],{"nctId":207,"briefTitle":208,"status":81,"phases":294,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":295,"interventions":296},[41],[17],[163,216,217],{"trials":298,"activeCount":49},[],{"trials":300,"activeCount":49},[],{"intervention":217,"totalTrials":11,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":315,"NA":317},{"trials":304,"activeCount":49},[],{"trials":306,"activeCount":49},[],{"trials":308,"activeCount":49},[],{"trials":310,"activeCount":49},[311],{"nctId":207,"briefTitle":208,"status":81,"phases":312,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":313,"interventions":314},[41],[17],[163,216,217],{"trials":316,"activeCount":49},[],{"trials":318,"activeCount":49},[],{"intervention":278,"totalTrials":11,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":333,"NA":335},{"trials":322,"activeCount":49},[],{"trials":324,"activeCount":49},[],{"trials":326,"activeCount":49},[],{"trials":328,"activeCount":49},[329],{"nctId":268,"briefTitle":269,"status":81,"phases":330,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":331,"interventions":332},[41],[276],[243,278],{"trials":334,"activeCount":49},[],{"trials":336,"activeCount":49},[],{"intervention":338,"totalTrials":339,"cells":340},"mogamulizumab",4,{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":378,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":342,"activeCount":49},[],{"trials":344,"activeCount":49},[345,355,368],{"nctId":346,"briefTitle":347,"status":81,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":201,"conditions":351,"interventions":353},"NCT02358473","Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer",[39],"2016-12","2015-01",[352],"Non-Small Cell Lung Cancer",[338,354],"Docetaxel",{"nctId":356,"briefTitle":357,"status":81,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":365},"NCT02301130","Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w\u002F Advanced Solid Tumors",[39],"2017-12-08","2018-03-05","2014-11-26",64,[364],"Advanced Solid Tumors",[338,366,367],"MEDI4736","tremelimumab",{"nctId":369,"briefTitle":370,"status":81,"phases":371,"primaryCompletion":372,"completion":372,"start":373,"enrollment":6,"conditions":374,"interventions":375},"NCT02867007","KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors",[39],"2019-12-15","2016-08",[22,24,26],[376,377],"KHK2455","Mogamulizumab",{"trials":379,"activeCount":49},[380],{"nctId":381,"briefTitle":382,"status":383,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":391},"NCT04745234","Mogamulizumab Q4week Dosing in Participants With R\u002FR CTCL","UNKNOWN",[40],"2025-05","2021-08-16",34,[389,390],"Cutaneous T-Cell Lymphoma, Relapsed","Cutaneous T-Cell Lymphoma Refractory",[377],{"trials":393,"activeCount":49},[],{"trials":395,"activeCount":49},[],{"trials":397,"activeCount":49},[],{"intervention":399,"totalTrials":8,"cells":400},"KHK4083",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":402,"activeCount":49},[],{"trials":404,"activeCount":49},[],{"trials":406,"activeCount":49},[407,418],{"nctId":408,"briefTitle":409,"status":81,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT03703102","Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis",[40],"2020-02-06","2020-11-12","2018-10-22",274,[416],"Atopic Dermatitis",[399],{"nctId":419,"briefTitle":420,"status":81,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":437},"NCT02647866","Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis",[40],"2018-09","2018-10","2016-06",66,[427,428,429,430,431,432,433,434,435,436],"Ulcerative Colitis","Digestive System Diseases","Colitis, Ulcerative","Colitis","Gastrointestinal Diseases","Inflammatory Bowel Diseases","Intestinal Diseases","Colonic Diseases","Autoimmune Disease","Abdominal Pain",[399],{"trials":439,"activeCount":49},[],{"trials":441,"activeCount":49},[],{"trials":443,"activeCount":49},[],{"intervention":445,"totalTrials":11,"cells":446},"KW-2871",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":448,"activeCount":49},[],{"trials":450,"activeCount":49},[],{"trials":452,"activeCount":49},[453],{"nctId":454,"briefTitle":455,"status":151,"phases":456,"primaryCompletion":154,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT00199342","A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",[39,40],"2004-11",5,[30],[445],{"trials":462,"activeCount":49},[],{"trials":464,"activeCount":49},[],{"trials":466,"activeCount":49},[],{"intervention":468,"totalTrials":11,"cells":469},"KRN23",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":471,"activeCount":49},[],{"trials":473,"activeCount":49},[],{"trials":475,"activeCount":49},[476],{"nctId":477,"briefTitle":478,"status":81,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT02312687","Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)",[40],"2018-11-30","2015-01-30",20,[17],[468],{"trials":486,"activeCount":49},[],{"trials":488,"activeCount":49},[],{"trials":490,"activeCount":49},[],{"intervention":262,"totalTrials":11,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":494,"activeCount":49},[],{"trials":496,"activeCount":49},[],{"trials":498,"activeCount":49},[499],{"nctId":252,"briefTitle":253,"status":81,"phases":500,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":501,"interventions":502},[40],[260],[243,262,263,264],{"trials":504,"activeCount":49},[],{"trials":506,"activeCount":49},[],{"trials":508,"activeCount":49},[],{"intervention":263,"totalTrials":11,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":512,"activeCount":49},[],{"trials":514,"activeCount":49},[],{"trials":516,"activeCount":49},[517],{"nctId":252,"briefTitle":253,"status":81,"phases":518,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":519,"interventions":520},[40],[260],[243,262,263,264],{"trials":522,"activeCount":49},[],{"trials":524,"activeCount":49},[],{"trials":526,"activeCount":49},[],{"intervention":264,"totalTrials":11,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":539,"PHASE4":541,"NA":543},{"trials":530,"activeCount":49},[],{"trials":532,"activeCount":49},[],{"trials":534,"activeCount":49},[535],{"nctId":252,"briefTitle":253,"status":81,"phases":536,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":537,"interventions":538},[40],[260],[243,262,263,264],{"trials":540,"activeCount":49},[],{"trials":542,"activeCount":49},[],{"trials":544,"activeCount":49},[],{"intervention":546,"totalTrials":11,"cells":547},"KW-6002",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":549,"activeCount":49},[],{"trials":551,"activeCount":49},[],{"trials":553,"activeCount":49},[554],{"nctId":555,"briefTitle":556,"status":81,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT00456586","12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg\u002FDay KW-6002 in Parkinson's Disease Patients on Levodopa\u002FCarbidopa",[40],"2003-05","2003-06","2002-04",180,[14],[546],{"trials":565,"activeCount":49},[],{"trials":567,"activeCount":49},[],{"trials":569,"activeCount":49},[],{"intervention":571,"totalTrials":11,"cells":572},"Mogamulizumab + Nivolumab",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":574,"activeCount":49},[],{"trials":576,"activeCount":49},[],{"trials":578,"activeCount":49},[579],{"nctId":580,"briefTitle":581,"status":81,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":590},"NCT02705105","Study of Mogamulizumab + Nivolumab in Subjects w\u002FLocally Advanced or Metastatic Solid Tumors",[39,40],"2018-08-22","2018-10-10","2016-02",114,[22,24,26,588,589],"Hepatocellular Carcinoma","HCC",[571],{"trials":592,"activeCount":49},[],{"trials":594,"activeCount":49},[],{"trials":596,"activeCount":49},[],{"intervention":598,"totalTrials":8,"cells":599},"KW-6356",{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":601,"activeCount":49},[],{"trials":603,"activeCount":49},[604,614],{"nctId":605,"briefTitle":606,"status":81,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT04190654","Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite",[39],"2020-03-20","2019-11-26",26,[612],"Hepatic Impairment",[598],{"nctId":615,"briefTitle":616,"status":81,"phases":617,"primaryCompletion":618,"completion":618,"start":619,"enrollment":15,"conditions":620,"interventions":622},"NCT04147910","Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356",[39],"2019-10-02","2019-08-21",[621],"Healthy Male Subjects",[598],{"trials":624,"activeCount":49},[],{"trials":626,"activeCount":49},[],{"trials":628,"activeCount":49},[],{"trials":630,"activeCount":49},[],{"intervention":632,"totalTrials":11,"cells":633},"Avelumab",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":635,"activeCount":49},[],{"trials":637,"activeCount":49},[638],{"nctId":639,"briefTitle":640,"status":151,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":646},"NCT03915405","KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer",[39],"2022-11-15","2019-09-26",16,[28],[376,632],{"trials":648,"activeCount":49},[],{"trials":650,"activeCount":49},[],{"trials":652,"activeCount":49},[],{"trials":654,"activeCount":49},[],{"intervention":354,"totalTrials":11,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":658,"activeCount":49},[],{"trials":660,"activeCount":49},[661],{"nctId":346,"briefTitle":347,"status":81,"phases":662,"primaryCompletion":349,"completion":349,"start":350,"enrollment":201,"conditions":663,"interventions":664},[39],[352],[338,354],{"trials":666,"activeCount":49},[],{"trials":668,"activeCount":49},[],{"trials":670,"activeCount":49},[],{"trials":672,"activeCount":49},[],{"intervention":674,"totalTrials":11,"cells":675},"KRN330",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":677,"activeCount":49},[],{"trials":679,"activeCount":49},[680],{"nctId":681,"briefTitle":682,"status":81,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT00575562","Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer",[39],"2010-01","2007-06",42,[688],"Colorectal Cancer",[674],{"trials":691,"activeCount":49},[],{"trials":693,"activeCount":49},[],{"trials":695,"activeCount":49},[],{"trials":697,"activeCount":49},[],{"intervention":366,"totalTrials":11,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":701,"activeCount":49},[],{"trials":703,"activeCount":49},[704],{"nctId":356,"briefTitle":357,"status":81,"phases":705,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":706,"interventions":707},[39],[364],[338,366,367],{"trials":709,"activeCount":49},[],{"trials":711,"activeCount":49},[],{"trials":713,"activeCount":49},[],{"trials":715,"activeCount":49},[],{"intervention":367,"totalTrials":11,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":719,"activeCount":49},[],{"trials":721,"activeCount":49},[722],{"nctId":356,"briefTitle":357,"status":81,"phases":723,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":724,"interventions":725},[39],[364],[338,366,367],{"trials":727,"activeCount":49},[],{"trials":729,"activeCount":49},[],{"trials":731,"activeCount":49},[],{"trials":733,"activeCount":49},[],{"intervention":735,"totalTrials":11,"cells":736},"KHK2823",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":738,"activeCount":49},[],{"trials":740,"activeCount":49},[741],{"nctId":742,"briefTitle":743,"status":151,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":751},"NCT02181699","Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",[39],"2019-05-10","2014-06",39,[749,750],"Acute Myeloid Leukemia","Myelodysplastic Syndrome",[735],{"trials":753,"activeCount":49},[],{"trials":755,"activeCount":49},[],{"trials":757,"activeCount":49},[],{"trials":759,"activeCount":49},[],{"intervention":761,"totalTrials":11,"cells":762},"Sancuso - Part 1",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":778,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":764,"activeCount":49},[],{"trials":766,"activeCount":49},[767],{"nctId":768,"briefTitle":769,"status":81,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":225,"conditions":774,"interventions":776},"NCT05027646","Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.",[39],"2021-12-22","2022-01-19","2021-07-06",[775],"Healthy Volunteers",[761,777],"Sancuso - Part 2",{"trials":779,"activeCount":49},[],{"trials":781,"activeCount":49},[],{"trials":783,"activeCount":49},[],{"trials":785,"activeCount":49},[],{"intervention":777,"totalTrials":11,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":789,"activeCount":49},[],{"trials":791,"activeCount":49},[792],{"nctId":768,"briefTitle":769,"status":81,"phases":793,"primaryCompletion":771,"completion":772,"start":773,"enrollment":225,"conditions":794,"interventions":795},[39],[775],[761,777],{"trials":797,"activeCount":49},[],{"trials":799,"activeCount":49},[],{"trials":801,"activeCount":49},[],{"trials":803,"activeCount":49},[],{"intervention":805,"totalTrials":11,"cells":806},"KW-2449",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":808,"activeCount":49},[],{"trials":810,"activeCount":49},[811],{"nctId":812,"briefTitle":813,"status":151,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":823},"NCT00346632","An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia",[39],"2008-04","2006-06",37,[819,820,821,822],"Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndromes","Chronic Myelogenous Leukemia",[805],{"trials":825,"activeCount":49},[],{"trials":827,"activeCount":49},[],{"trials":829,"activeCount":49},[],{"trials":831,"activeCount":49},[],{"intervention":376,"totalTrials":18,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":835,"activeCount":49},[],{"trials":837,"activeCount":49},[838,842],{"nctId":639,"briefTitle":640,"status":151,"phases":839,"primaryCompletion":642,"completion":642,"start":643,"enrollment":644,"conditions":840,"interventions":841},[39],[28],[376,632],{"nctId":369,"briefTitle":370,"status":81,"phases":843,"primaryCompletion":372,"completion":372,"start":373,"enrollment":6,"conditions":844,"interventions":845},[39],[22,24,26],[376,377],{"trials":847,"activeCount":49},[],{"trials":849,"activeCount":49},[],{"trials":851,"activeCount":49},[],{"trials":853,"activeCount":49},[854],{"nctId":855,"briefTitle":856,"status":857,"phases":858,"conditions":859,"interventions":861},"NCT04321694","Expanded Access for KHK2455","NO_LONGER_AVAILABLE",[],[860],"Glioblastoma Multiforme",[376]]